Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Piramal Enterprises - Pharma day highlights - ICICI Securities

Posted On: 2021-02-28 23:13:26 (Time Zone: Arizona, USA)

Piramal Enterprises (PEL) has uniquely positioned itself in the pharma business to not only leverage from its niche business model but also capitalise the upcoming organic and inorganic opportunities that augurs well for future growth. PEL organised a virtual conference to discuss the pharma business in great depth and we have encapsulated the key highlights from that discussion below.

- CDMO - PEL is the 13th largest player in the global CDMO market with an approximate target market size of US$55-70bn. Company generates most of its revenues from commercial manufacturing and development services by servicing clients across the spectrum (big pharma, generics, emerging biopharma, etc). It has about ~80 active projects with ~30 being in the ph-3 stage spanning across complex product verticals (ADC, HPAPI, API, OSD, fill finish, etc). Company has a strong order book across the globe it is particularly strong in US and UK where it is able to provide integrated services for complex products. It is also justified by the fact that ~75% of the revenue is contributed from developed markets. Company is confident of growing faster in the next five years as compared to the previous five years with gradual margin improvement. We expect CDMO to CAGR at 12.0% over FY21E-FY23E.

- Complex hospital generics (CHG) - PEL is the 4th largest player (3rd ex-China) in the global Complex hospital generics market with an approximate target market size of >US$50bn. Inhalation anesthesia is the largest revenue contributor for PEL (~55%) followed by injectable anesthesia & pain management and intrathecal therapy with each contributing ~20-25%. However, the industry size for injectables is much larger than that of inhalation and company believes that this will be the faster growing segment in the future led by new products and entry into newer geographies. PEL has locked an order from Vizient, one of the largest GPO in US for a new product which will be launched soon. Desflurane is under review with USFDA and its launch is expected in next fiscal. We expect CHG to CAGR at 13.0% over FY21E-FY23E.

- Consumer healthcare - PEL is ranked 11th in the Indian OTC segment with an approximate target market size of US$6-10bn. Currently, company has a basket of 21 products with core brands (Saridon, Supradyn, Lacto Calamine, I-pill and Little's) contributing ~60% to the revenue. Its top three product categories (Analgesics, Skin care and Vitamins) generate ~70% of the revenue. PEL utilizes a multi-channel approach to increase its reach across the country. Apart from e-commerce, PEL has a physical reach across more than 200,000 outlets with a ground force of ~1,200 in ~1,500 towns. We expect OTC to CAGR at 12.5% over FY21E-FY23E with sharp margin improvement.

- PEL will explore the PLI scheme and apply if its beneficial.

- Valuation and risks: PEL has reduced its net debt in the pharma business from US$545mn to US$359mn in 9MFY21 supported by the 20% equity dilution to Carlyle (completed in Oct'20). We value the Global Pharma business at 13xMar'23 EV/EBITDA and the India consumer products business at 3xMar'23 EV/Sales. Maintain BUY with SoTP-based revised target price of Rs2,265 (earlier: Rs2,059). Key downside risks are: delay in product approvals and launch, regulatory hurdles, and forex volatility.

Shares of PIRAMAL ENTERPRISES LTD. was last trading in BSE at Rs.1831.4 as compared to the previous close of Rs. 1950.4. The total number of shares traded during the day was 139505 in over 7894 trades.

The stock hit an intraday high of Rs. 1951.25 and intraday low of 1810.1. The net turnover during the day was Rs. 263685540.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Nestle India 1QCY21 results - Views by Himanshu Nayyar, Lead Analyst - Institutional Equities, YES SECURITIES

ICICI Prudential Life Insurance - Q4FY21 Result Update - YES Securities

Power: Sector Thematic - Reforms essential for renaissance - HDFC Securities

ACC 1QCY21 Results Review Report - Strong margins! - HDFC Securities

ICICI Prudential Life 4QFY21 Results Review Report - Strong micro; challenging macro - HDFC Securities

ACC Ltd - Q1CY21 Result Update - YES Securities

ICICI Prudential Life Insurance - Business momentum upwards; valuations remain attractive - ICICI Securities

Multiplex - Business disruption again - learnings and better cash position to help - ICICI Securities

ACC - Strong show led by lower costs - ICICI Securities

Brookfield India REIT - Building a strong edifice - ICICI Securities

Q4FY21 Result Preview - Oil & Gas - ICICI Direct

Q1CY21 Result Update - ACC Ltd - ICICI Direct

ACC Q1CY21 Results - Views by YES SECURITIES

Comments on Rupee from industry experts - April 19, 2021

Autos & Logistics 4QFY21 Results Preview - HDFC Securities

ADD on Mindtree - Gaining momentum - HDFC Securities

ICICI Lombard 4QFY21 Result Review - HDFC Securities

Mindtree - Q4FY21 Result Update - YES Securities

ICICI Lombard - Q4FY21 Result Update - YES Securities

HDFC Bank - Q4FY21 Result Update - YES Securities

Mindtree - Subtle downgrade in outlook! - ICICI Securities

SBI Cards and Payment Services - Play on monetisable payments growth - ICICI Securities

ICICI Lombard General Insurance Company - Cyclical recovery can protract; fundamentals remain intact - ICICI Securities

HDFC Bank - Resilience and consistency displayed to its core - ICICI Securities

Home First Finance Company - Tech-led affordable housing play at affordable valuations - ICICI Securities

Q4FY21 Result Update - Wipro Ltd - ICICI Direct

ICICI Direct - Covid Recovery Pulse - E-Way bill generation ends March 2021 on strong note...

Derivatives Strategy - Positional Future - ICICI Direct

Gladiator Stocks - Escorts - ICICI Direct

Q4FY21 Company Update - Tata Metaliks - ICICI Direct

Q4FY21 Result Update - MindTree Ltd - ICICI Direct

Q4FY21 Result Update - HDFC Bank - ICICI Direct

ICICI Direct Derivatives Weekly View (April 16): Sustainability above 14700 may trigger fresh uptrend...

Market Outlook - Technical - By Dharmesh Shah, Head - Technical, ICICIdirect

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on Monsoon outlook

ADD on Wipro - Improving growth visibility - HDFC Securities

Building Materials 4QFY21 Results Preview - Strong demand to support robust margin - HDFC Securities

Consumer Discretionary 4QFY21 Results Preview - Bargains few and far between - HDFC Securities

Consumer Durables 4QFY21 Results Preview - HDFC Securities

Wipro - Q4FY21 Result Update - YES Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 Monthly Trade Balance

Wipro - Q4FY21 Result Update - Lofty multiples leave limited margin of safety - ICICI Securities

FMCG & Alco Bev 4QFY21 Results Preview - HDFC Securities

Maintain BUY on Infosys - Q4FY21 Results Review - Buy the dip - HDFC Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on March 2021 WPI Data released today

Non-leveraged financials 4QFY21 Results Preview - HDFC Securities

Infosys - A reality check! - ICICI Securities

Infosys - Q4FY21 Result Update - YES Securities

Polymer price tracker - PVC prices continue to rise - April 15, 2021 - ICICI Securities

Bharti Airtel - Restructuring aimed at digital biz, AGR-tax efficiency - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020